NCT05042180

Brief Summary

The study is a single-blinded, randomized, controlled, 12 months clinical trial. The objective is to investigate the feasibility, effects and side-effects of virtual reality-assisted cognitive behavioral therapy (VR-CBT) vs. cognitive behavioral therapy (CBT) in patients with a diagnosis of alcohol dependence.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
102

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Oct 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 27, 2021

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 13, 2021

Completed
23 days until next milestone

Study Start

First participant enrolled

October 6, 2021

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2024

Completed
Last Updated

November 10, 2021

Status Verified

November 1, 2021

Enrollment Period

2.4 years

First QC Date

July 27, 2021

Last Update Submit

November 9, 2021

Conditions

Keywords

AlcoholAddictionVirtual RealityExposure TherapyCognitive Behavioral Therapy

Outcome Measures

Primary Outcomes (1)

  • Reduction in total alcohol consumption

    Percent change in alcohol consumption, defined as "x" grams of alcohol for past 30 days. This will be registered using the Timeline-Follow-Back (TLFB) method.

    Baseline, 6 months, 9 months, 12 months

Secondary Outcomes (12)

  • Change in heavy drinking days

    Baseline, 6 months, 9 months, 12 months

  • Change in Alcohol Users Identification Test (AUDIT) score

    Baseline, 6 months, 9 months, 12 months

  • Change in Drug User Identification Test (DUDIT) score

    Baseline, 6 months, 9 months, 12 months

  • Change in Penn Alcohol Craving Scale (PACS) score

    Baseline, 6 months, 9 months, 12 months

  • Screening for Cognitive Impairment in Psychiatry (SCIP) score

    Baseline, 6 months, 9 months, 12 months

  • +7 more secondary outcomes

Study Arms (2)

Virtual Reality Cognitive Behavioral Therapy (VRCBT)

EXPERIMENTAL

The VR exposure is performed to induce alcohol craving and high-risk induced reactions during the therapy session, in order to trigger a lifelike response to alcohol, while the therapist is present and able to train the participant in applying CBT-based coping strategies to deal with the alcohol cravings.

Behavioral: Virtual Reality Cognitive Behavioral Therapy (CRAVR)

Cognitive Behavioral Therapy (CBT)

ACTIVE COMPARATOR

CBT is made up of the following elements: i) recognition (ii) avoiding and (iii) overcoming drinking cravings in high-risk situations with the aim of preventing relapse.

Behavioral: CBT

Interventions

Participants in the intervention group will scheduled for 14 treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations in virtual reality. VR-assisted gradual exposure therapy is integrated as a part of CBT. I.e. VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.

Virtual Reality Cognitive Behavioral Therapy (VRCBT)
CBTBEHAVIORAL

The active comparator receives 14 conventional cognitive behavioral therapy sessions with

Cognitive Behavioral Therapy (CBT)

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Informed oral and written consent
  • Meets criteria for alcohol dependence syndrome according to International Classification of Diseases (ICD) 10, WHO \& Diagnostic and Statistical Manual of Mental Disorder (DSM-5)
  • Age 18 - 70 years old (both included)
  • Minimum 5 'heavy drinking days' in the last month, which is defined as an alcohol intake above 60/48 grams or 5/4 items per. day for resp. men and women over the past 30 days

You may not qualify if:

  • Other active substance use defined by DUDIT score\> 6 (for men)\> 2 (for women) and meet the criteria for other drug dependence according to ICD-10 (excluding nicotine)
  • Does not speak or understand Danish
  • Mental retardation or known severe psychiatric illness or other condition where it is assessed that will interfere with participation eg severely impaired vision or hearing.
  • Medical alcohol treatment (disulfiram, acamprosate, naltrexone or nalmefen) within the latest 4 weeks and during the treatment period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Novavi ambulatorierne

Copenhagen, Frederiksberg, 2000, Denmark

RECRUITING

Related Publications (2)

  • Thaysen-Petersen D, Hammerum SK, Vissing AC, Oestrich IH, Nordentoft M, During SW, Fink-Jensen A. Virtual reality-assisted cognitive behavioral therapy for patients with alcohol use disorder: a randomized feasibility study. Front Psychiatry. 2024 Feb 14;15:1337898. doi: 10.3389/fpsyt.2024.1337898. eCollection 2024.

  • Thaysen-Petersen D, Hammerum SK, Vissing AC, Arnfred BT, Nordahl R, Adjorlu A, Nordentoft M, Oestrich IH, During SW, Fink-Jensen A. Virtual reality-assisted cognitive behavioural therapy for outpatients with alcohol use disorder (CRAVR): a protocol for a randomised controlled trial. BMJ Open. 2023 Mar 29;13(3):e068658. doi: 10.1136/bmjopen-2022-068658.

MeSH Terms

Conditions

AlcoholismBehavior, Addictive

Condition Hierarchy (Ancestors)

Alcohol-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental DisordersCompulsive BehaviorImpulsive BehaviorBehavior

Central Study Contacts

Anders Fink-Jensen, MD, DMSc

CONTACT

Daniel Thaysen Petersen, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: single-blinded, randomized, controlled
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, MD, DMSci

Study Record Dates

First Submitted

July 27, 2021

First Posted

September 13, 2021

Study Start

October 6, 2021

Primary Completion

March 1, 2024

Study Completion

March 1, 2024

Last Updated

November 10, 2021

Record last verified: 2021-11

Data Sharing

IPD Sharing
Will not share

Locations